Clinical profile of responders to adaptive servo-ventilation: a cluster analysis from the READ-ASV European cohort
Abstract
BACKGROUND: Adaptive servo-ventilation (ASV) effectively treats central sleep apnea (CSA), with or without coexisting obstructive sleep apnea (CSA-OSA). However, this is a diverse patient group, and the characteristics of patients who are most likely to benefit from ASV therapy, outside of traditional etiology-based subgroups, are unknown. OBJECTIVES: To identify clusters of ASV-treated patients based on anthropometric data and comorbidities, and to evaluate the differential response to ASV in these patient clusters. METHODS: This analysis used data from the READ-ASV registry, which enrolled adults with CSA prescribed ASV from September 2017-March 2021. Evaluations included the Epworth Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, Pittsburg Sleep Quality Index, EuroQol-5-dimension, and sleep study data. Latent class analysis was used to identify patient clusters based on baseline anthropometric data and comorbidities. RESULTS: Of 812 patients, 421 (52%) were in Cluster (C) 1 (older, high rate of cardiovascular comorbidities [including stroke], high body mass index [BMI]), 239 (29%) were in C2 (elderly/middle-aged, average-low cardiovascular comorbidity rate, high stroke rate, lower BMI, low diabetes rate), and 152 (19%) were in Cluster 3 (younger, low cardiovascular comorbidity rate, higher BMI, high depression rate). Patients from C3 versus C1/C2 had the highest apnea-hypopnea index at baseline (55 vs. 48/39.5 events/h), were the most symptomatic, had the worst quality of life (QoL), and had the greatest symptomatic and QoL improvement on ASV. They remained the most symptomatic cluster after treatment. CONCLUSIONS: The identification of subgroups of ASV users with differing responses to therapy and residual symptom burden could facilitate a more personalized approach to ASV prescription and therapy management. CLINICAL TRIAL REGISTRATION: https://www. CLINICALTRIALS: gov; NCT03032029.
Related
- Serum miRNA expression profile in responders to acupuncture treatment for diminished ovarian reserve: a study protocol for a nested case-control study.
- European Code Against Cancer receptivity: latent profile analysis across four European countries
- Dupilumab efficacy in children aged 6 months to younger than 6 years with moderate-to-severe atopic dermatitis and clinical characteristics of early super-responders.
- Defining the clinical benefits of disease-modifying therapy in people living with spinal muscular atrophy who require permanent ventilation: a UK-based modified Delphi consensus process
- Understanding underserved and underrepresented populations in European clinical studies: a narrative review with systematic approach
BibTeX
@article{pepin2026clinical,
title = {{Clinical profile of responders to adaptive servo-ventilation: a cluster analysis from the READ-ASV European cohort}},
author = {Jean-Louis Pépin and Raphael Heinzer and Sébastien Bailly and Florent Lavergne and Adam Benjafield and Susanne Fischer and Holger Woehrle and Michael Arzt},
journal = {Sleep Medicine},
year = {2026},
month = sep,
doi = {10.1016/j.sleep.2026.109085},
url = {https://hal.science/hal-05744105v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical profile of responders to adaptive servo-ventilation: a cluster analysis from the READ-ASV European cohort
AU - Jean-Louis Pépin
AU - Raphael Heinzer
AU - Sébastien Bailly
AU - Florent Lavergne
AU - Adam Benjafield
AU - Susanne Fischer
AU - Holger Woehrle
AU - Michael Arzt
PY - 2026
DA - 2026/09/09
JO - Sleep Medicine
DO - 10.1016/j.sleep.2026.109085
UR - https://hal.science/hal-05744105v1
AB - BACKGROUND: Adaptive servo-ventilation (ASV) effectively treats central sleep apnea (CSA), with or without coexisting obstructive sleep apnea (CSA-OSA). However, this is a diverse patient group, and the characteristics of patients who are most likely to benefit from ASV therapy, outside of traditional etiology-based subgroups, are unknown. OBJECTIVES: To identify clusters of ASV-treated patients based on anthropometric data and comorbidities, and to evaluate the differential response to ASV in these patient clusters. METHODS: This analysis used data from the READ-ASV registry, which enrolled adults with CSA prescribed ASV from September 2017-March 2021. Evaluations included the Epworth Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, Pittsburg Sleep Quality Index, EuroQol-5-dimension, and sleep study data. Latent class analysis was used to identify patient clusters based on baseline anthropometric data and comorbidities. RESULTS: Of 812 patients, 421 (52%) were in Cluster (C) 1 (older, high rate of cardiovascular comorbidities [including stroke], high body mass index [BMI]), 239 (29%) were in C2 (elderly/middle-aged, average-low cardiovascular comorbidity rate, high stroke rate, lower BMI, low diabetes rate), and 152 (19%) were in Cluster 3 (younger, low cardiovascular comorbidity rate, higher BMI, high depression rate). Patients from C3 versus C1/C2 had the highest apnea-hypopnea index at baseline (55 vs. 48/39.5 events/h), were the most symptomatic, had the worst quality of life (QoL), and had the greatest symptomatic and QoL improvement on ASV. They remained the most symptomatic cluster after treatment. CONCLUSIONS: The identification of subgroups of ASV users with differing responses to therapy and residual symptom burden could facilitate a more personalized approach to ASV prescription and therapy management. CLINICAL TRIAL REGISTRATION: https://www. CLINICALTRIALS: gov; NCT03032029.
SN - 1389-9457
SN - 1878-5506
ER -